Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 14Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangiosarcoma 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Gemcitabine 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2spartalizumab 1peginterferon alfa-2a 1balstilimab 1RNA, Messenger 1Paclitaxel 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hemangiosarcoma × Ipilimumab × Clear all
NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡